MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 6 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Holders of 5% or more of MLTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of MoonLake Immunotherapeutics, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13D/A | 27.70%19.8M shares | – | Nov 10, 20251 filing | Nov 10, 2025 | SEC |
| Deep Track Capital, LP | 13G | 6.46%4.61M shares | New | Nov 12, 20251 filing | Nov 12, 2025 | SEC |
| Cormorant Asset Management, LP | 13G | 6.10%4.36M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
11 Schedule 13D and 13G filings on MoonLake Immunotherapeutics, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 20263:01 PM ET | Cormorant Asset Management, LPand 1 other | 13G | 6.10%4.36M shares | New | Dec 31, 2025 | SEC |
| Nov 14, 20259:03 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 3.15%2.00M shares | −3.35 ppfrom 6.50%Below 5% | Sep 30, 2025 | SEC |
| Nov 12, 20254:02 PM ET | Deep Track Capital, LPand 2 others | 13G | 6.46%4.61M shares | New | Nov 5, 2025 | SEC |
| Nov 10, 20255:27 PM ET | Biotechnology Value Fund L Pand 10 others | 13D/A | 27.70%19.8M shares | – | Nov 6, 2025 | SEC |
| Nov 5, 202511:40 AM ET | FMR LLCand 1 other | 13G/A | 1.10%726.9K shares | −7.90 ppfrom 9.00%Below 5% | Sep 30, 2025 | SEC |
| Oct 1, 20255:23 PM ET | Chen Bihua | 13G/A | 3.14%1.99M shares | –Below 5% | Sep 30, 2025 | SEC |
| Aug 14, 20256:57 AM ET | Avoro Capital Advisors LLCand 1 other | 13G | 6.50%4.15M shares | New | Jun 30, 2025 | SEC |
| Aug 6, 202512:06 PM ET | FMR LLCand 1 other | 13G/A | 9.00%5.70M shares | −1.00 ppfrom 10.00% | Jun 30, 2025 | SEC |
| May 14, 202510:45 AM ET | Price T Rowe Associates Inc | 13G/A | 4.70%2.97M shares | −0.60 ppfrom 5.30%Below 5% | Mar 31, 2025 | SEC |
| Feb 14, 20259:44 AM ET | Price T Rowe Associates Inc | 13G | 5.30%3.34M shares | New | Dec 31, 2024 | SEC |
| Feb 12, 20259:30 AM ET | FMR LLCand 1 other | 13G/A | 10.00%6.31M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell MoonLake Immunotherapeutics shares.
No Form 144 notices for MoonLake Immunotherapeutics are on file.